Top

Child's Nervous System

Published in:

01-04-2014 | Review Paper

RETRACTED ARTICLE: Subependymal giant cell astrocytoma: current concepts, management, and future directions

Authors: Taohui Ouyang, Na Zhang, Thomas Benjamin, Long Wang, Jiantong Jiao, Yiqing Zhao, Jian Chen

Published in: Child's Nervous System | Issue 4/2014

Abstract

Background

Subependymal giant cell astrocytoma (SEGA) is the most common central nervous system tumor in patients with tuberous sclerosis complex (TSC). SEGAs are generally benign, non-infiltrative lesions, but they can lead to intracranial hypertension, obstructive hydrocephalus, focal neurologic deficits, and even sudden death.

Discussion

Surgical resection has been the standard treatment for SEGAs, and it is generally curative with complete resection. However, not all SEGAs are amenable to safe and complete resection. Gamma Knife stereotactic radiosurgery provides another treatment option as a primary or adjuvant treatment for SEGAs, but it has highly variable response effects with sporadic cases demonstrating its efficacy. Recently, biologically targeted pharmacotherapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus and everolimus has provided a safe and efficacious treatment option for patients with SEGAs. However, SEGAs can recur few months after drug discontinuation, indicating that mTOR inhibitors may need to be continued to avoid recurrence. Further studies are needed to evaluate the advantages and adverse effects of long-term treatment with mTOR inhibitors. This review presents an overview of the current knowledge and particularly highlights the surgical and medical options of SEGAs in patients with TSC.

Ichikawa T, Wakisaka A, Daido S, Takao S, Tamiya T, Date I (2005) A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism. J Mol Diagn 7:544–549PubMedCentralCrossRefPubMed

Kwiatkowska J, Wigowska-Sowinska J, Napierala D, Slomski R, Kwiatkowski DJ (1999) Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. N Engl J Med 340:703–707CrossRefPubMed

Souweidane MM, Luther N (2006) Endoscopic resection of solid intraventricular brain tumors. J Neurosurg 105:271–278CrossRefPubMed

Hahn JS, Bejar R, Gladson CL (1991) Neonatal subependymal giant cell astrocytoma associated with tuberous sclerosis: MRI, CT and ultrasound correlation. Neurology 41:124–128CrossRefPubMed

Medhkour A, Traul D, Hussain N (2002) Neonatal subependymal giant cell astrocytoma. Pediatr Neurosurg 36:271–274CrossRefPubMed

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropsychiatrica 114:97–109

Byard RW, Blumbergs PC, James RA (2003) Mechanisms of unexpected death in tuberous sclerosis. J Forensic Sci 48:172–176CrossRefPubMed

Brown JM (1975) Tuberose sclerosis with malignant astrocytoma. Med J Aust 1:811–814PubMed

Waga S, Yamamoto Y, Kojima T, Sakakura M (1977) Massive hemorrhagein tumor of tuberous sclerosis. Surg Neurol 8:99–101PubMed

10.

Koenig MK, Butler IJ, Northrup H (2008) Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23:1238–1239PubMedCentralCrossRefPubMed

11.

Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DM (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811CrossRefPubMed

12.

Russell DS, Rubenstein LJ, Lumsden CE (1959) Tuberose sclerose (Bourneville’s disease), subependymal giant-cell astrocytomas: tuberose sclerosis, spongio neuroblastoma and tuberose sclerosis. In: Russell DS, Rubenstein LJ, editors. Pathology of tumours of the nervous system. London: Edward Arnold p. 29-30. 105–6, 169

13.

Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, Prokop M (2009) Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 16:691–696CrossRefPubMed

14.

Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461CrossRefPubMed

15.

Shepherd CW, Gómez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66:792–796CrossRefPubMed

16.

Takata K, Gaspareto EL, Da Costa LC, Lucato LT, Reed UC, Matushita H, de Aguiar PHP, Rosemberg S (2007) Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases. Arq Neuropsiquiatr 65:313–316CrossRefPubMed

17.

Raju GP, Urion DK, Sahin M (2007) Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol 36:128–131CrossRefPubMed

18.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R (2012) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, Available online 13 November

19.

Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C (1999) Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 66:370–375PubMedCentralCrossRefPubMed

20.

Sinson G, Sutton LN, Yachnis AT, Duhaime AC, Schut L (1994) Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 20:233–239CrossRefPubMed

21.

Fujiwara S, Takaki T, Hikita T, Nishio S (1989) Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow? Childs Nerv Syst 5:43–44CrossRefPubMed

22.

Debiec-Rychter M, Jesionek-Kupnicka D, Zakrzewski K, Liberski PP (1999) Cytogenetic changes in two cases of subependymal giant-cell astrocytoma. Cancer Gente Cytogenet 109:29–33CrossRef

23.

Sharma MC, Ralte AM, Gaekwad S, Santosh V, Shankar S, Sarkar C (2004) Subependimal giant cell astrocytoma—a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 10:219–224CrossRefPubMed

24.

Sharma MC, Ralte AM, Arora R, Santosh V, Shankar SK, Sarkar C (2004) Subependymal giant cell astrocytoma—a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 10(4):219–224CrossRefPubMed

25.

Anna MB, Alessandro F, Francesca C, Chiara FG, Federico M, Flavio G, Genitori L, Taddei GL (2009) Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology 29:25–30CrossRef

26.

Heon Y, Young Im K, Soo Young I, Haeyoung SK, Sun Ha P, Sung-Hye P, Kim DG, Jung HW (2005) Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neuro-Oncol 74:1–8CrossRef

27.

Bonnin JM, Rubinstein LJ (1984) Immunohistochemistry of central nervous system tumors. Its contribution to neurosurgical diagnosis. J Neurosurg 60:1121–1133CrossRefPubMed

28.

Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19:232–243PubMed

29.

Shepherd CW, Scheithauer BW, Gomez MR, Altermatt HJ, Katzmann JA (1991) Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study. Neurosurgery 28:864–868CrossRefPubMed

30.

Menor F, Marti-Bonmati L, Mulas F, Poyatos C, Cortina H (1992) Neuroimaging in tuberous sclerosis: a clinicoradiological evaluation in pediatric patients. Pediatr Radiol 22:485–489CrossRefPubMed

31.

Sepp T, Yates JR, Green AJ (1996) Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 33:962–964PubMedCentralCrossRefPubMed

32.

Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 69:493–503PubMedCentralCrossRefPubMed

33.

Baskin HJ Jr (2008) The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol 38:936–952CrossRefPubMed

34.

Jozwiak J, Jozwiak S, Wlodarski P (2008) Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9:73–79CrossRefPubMed

35.

Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14:251–258CrossRef

36.

Zhang H, Cicchetti G, Onda H (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts P13K–Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223–1233PubMedCentralCrossRefPubMed

37.

Lin Y, Henderson P, Pettersson S, Satsangi J, Hupp T, Stevens C (2011) Tuberous sclerosis-2(TSC2) regulates the stability of death-associated protein kinase-1(DAPK) through a lysosome-dependent degradation pathway. FEBS J 278(2):354–370CrossRefPubMed

38.

Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin Kowalik J, Katarzyna K, David JK (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236–1242CrossRefPubMed

39.

Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B (2010) Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Am J Pathol 176(4):1878–1890PubMedCentralCrossRefPubMed

40.

Cross JH (2005) Neurocutaneous syndromes and epilepsy-issues in diagnosis and management. Epilepsia 46(Suppl 10):17–23CrossRefPubMed

41.

Gomez MR (1999) Natural history of cerebral tuberous sclerosis. In: Gomez MR, Sampson JR, Whittemore VH (eds) Tuberous Sclerosis Complex: Developmental Perspectives in Psychiatry. Oxford University Press, New York, pp 29–46

42.

Jambaque I, Cusmai R, Curatolo P, Cortesi F, Perrot C, Dulac O (1991) Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings. Dev Med Child Neurol 33:698–705CrossRefPubMed

43.

O’Callaghan FJ, Harris T, Joinson C, Bolton P, Noakes M, Presdee D, Renowden S, Shiell A, Martyn CN, Osborne JP (2004) The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 89:530–533PubMedCentralCrossRefPubMed

44.

Osborne J, Webb D (1993) Seizures and intellectual disability associated with tuberous sclerosis. Dev Med Child Neurol 35:276PubMed

45.

Gregory LH, Carl ES, The Tuberous Sclerosis Study Group (2007) Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 48(4):617–630

46.

de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Catherine C, Olivier D (2007) Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 60:83–89CrossRefPubMed

47.

Moavero R, Pinci M, Bombardieri R, Curatolo P (2011) The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Childs Nerv Syst 27:1203–1210CrossRefPubMed

48.

Torres VE, King BF, McKusick MA, Bjornsson J, Zincke H (2001) Update on tuberous sclerosis complex. Contrib Nephrol 136:33–49CrossRefPubMed

49.

Jiang T, Jia G, Ma Z, Luo S, Zhang Y (2011) The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst 27:55–62CrossRefPubMed

50.

Park KJ, Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD (2011) Gamma Knife surgery for subependymal giant cell astrocytomas. J Neurosurg 114:808–813CrossRefPubMed

51.

Lopes MBS, Wiestler OD, Stemmer-Rachamimov AO, Sharma MC (2007) Tuberous sclerosis complex and subependymal giant cell astrocytoma, in Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): WHO Classification of Tumours of the Central Nervous System, ed 4. Lyon: IARC Press Vol 1, pp 218–221

52.

Hyman MH, Whittemore VH (2000) National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662–665CrossRefPubMed

53.

Roach ES, DiMario FJ, Kandt RS, Northrup H (1999) Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 14:401–407CrossRefPubMed

54.

Berhouma M (2010) Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon’s perspective. World J Pediatr 6:103–110CrossRefPubMed

55.

Kim SK, Wang KC, Cho BK, Jung HW, Lee YJ, Chung YS, Lee JY, Park SH, Kim YM, Choe G, Chi JG (2001) Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 52:217–225CrossRefPubMed

56.

Boogaarts HD, Decq P, Grotenhuis JA, Le GC, Nseir R, Jarraya B, Djindjian M, Michel D, Tjemme B (2011) Long-term results of the neuroendoscopic management of colloid cysts of the third ventricle: a series of 90 cases. Neurosurgery 68:179–187CrossRefPubMed

57.

Cai R, Di X (2010) Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas. World Neurosurg 73:713–718CrossRefPubMed

58.

Beems T, Grotenhuis JA (2001) Subependymal giant cell astrocytoma in tuberous sclerosis: endoscopic images and the implications for therapy. Minim Invasive Neurosurg 44:58–60CrossRefPubMed

59.

Cappabianca P, Cinalli G, Gangemi M, Brunori A, Cavallo L, deDivitiis E, Decq P, Delitala A, Di Rocco F, Frazee J, Godano U, Grotenhuis A, Longatti P (2008) Application of neuroendoscopy to intraventricular lesions. Neurosurgery 62(suppl2):575–597PubMed

60.

Shepherd CW, Gomez MR (1991) Mortality in the Mayo Clinic Tuberous Sclerosis Complex Study. Ann NY Acad Sci 615:375–377CrossRefPubMed

61.

Franz DN, de Vries PJ, Crino PB (2009) Giant cell astrocytomas in tuberous sclerosis complex. Arch Dis Child 94:75–76PubMed

62.

Henderson MA, Fakiris AJ, Timmerman RD, Worth RM, Lo SS, Witt TC (2009) Gamma Knife stereotactic radiosurgery for low-grade astrocytomas. Stereotact Funct Neurosurg 87:161–167CrossRefPubMed

63.

Park YG, Kim EY, Chang JW, Chung SS (1997) Volume changes following gamma knife radiosurgery of intracranial tumors. Surg Neurol 48:488–493CrossRefPubMed

64.

Wang LW, Shiau CY, Chung WY, Wu HM, Guo WY, Liu KD, Ho DMT, Wong TT, Pan DHC (2006) Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience. J Neurosurg 105(suppl):127–132

65.

Park KJ, Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD (2011) Gamma Knife surgery for subependymal giant cell astrocytomas. Clinical article. J Neurosurg 114:808–813CrossRefPubMed

66.

Matsumura H, Takimoto H, Shimada N, Hirata M, Ohnishi T, Hayakawa T (1998) Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir (Tokyo) 38:287–291CrossRef

67.

Torres OA, Roach ES, Delgado MR, Sparagana SP, Sheffield E, Swift D, Bruce D (1998) Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 13:173–177CrossRefPubMed

68.

Perek-Polnik M, Jozwiak S, Jurkiewicz E, Perek D, Kotulska K (2012) Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur J Paediatr Neurol 16:83–85CrossRefPubMed

69.

Franz DN (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 11:1181–1192

70.

Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G et al (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498CrossRefPubMed

71.

Birca A, Mercier C, Major P (2010) Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr 6:381–384CrossRefPubMed

72.

Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisburyand S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140–151PubMedCentralCrossRefPubMed

73.

Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U (2010) Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 54:476–479CrossRefPubMed

74.

Holmes GL, Stafstrom CE (2007) Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsi 48:617–630CrossRef

75.

Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA (2010) The natural history of epilepsyin tuberous sclerosis complex. Epilepsia 51:1236e41

76.

Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372(9639):657e68CrossRef

77.

Jansen FE, Braams O, Vincken KL, Algra A, Anbeek P, Jennekens-Schinkel A, Halley D, Zonnenberg BA, Ouweland A, Huffelen AC, Nieuwenhuizen O, Nellist M (2008) Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology 70:908e15

78.

Wong M (2012) mTOR as a potential treatment target for epilepsy. Future Neurol 7(5):537–545PubMedCentralCrossRefPubMed

79.

Graham KF, Haddick PC, Jan YN, Jan LY (2006) Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 314:144–148CrossRef

80.

Wang Y, Barbaro MF, Baraban SC (2006) A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett 401:35–39CrossRefPubMed

81.

Wilfong A, Krueger DA, Holland-Bouley K (2011) Everolimus improves seizure control in tuberous sclerosis complex. Presented at: American Epilepsy Society Annual Meeting Baltimore, MD, USA, (Late-breaking Abstract 3.329)

82.

Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ et al (2008) Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med 14:843–848PubMedCentralCrossRefPubMed

83.

Govindarajan B, Mizesko MC, Miller MS, Onda H, Nunnelley M, Casper K, Brat D, Cohen C, Arbiser JL (2003) Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in vivo tumor growth. Clin Cancer Res 9:3469–3475PubMed

84.

Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P (2007) Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromol Med 9:117–127CrossRef

85.

Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151–3171CrossRefPubMed

86.

Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA (1997) Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137:481–492PubMedCentralCrossRefPubMed

87.

Pullikuth AK, Catling AD (2007) Scaffold mediated regulation of MAPK signaling and cytoskeletal dynamics: a perspective. Cell Signal 19:1621–1632PubMedCentralCrossRefPubMed

88.

Yalon M, Ben-Sira L, Constantini S, Toren A (2011) Regression of subependymal giant cell astrocytomas with RAD001 (everolimus) in tuberous sclerosis complex. Childs Nerv Syst 27:179–181CrossRefPubMed

Title: RETRACTED ARTICLE: Subependymal giant cell astrocytoma: current concepts, management, and future directions
Authors: Taohui Ouyang
Na Zhang
Thomas Benjamin
Long Wang
Jiantong Jiao
Yiqing Zhao
Jian Chen
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: Child's Nervous System / Issue 4/2014
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-014-2383-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

RETRACTED ARTICLE: Subependymal giant cell astrocytoma: current concepts, management, and future directions

Abstract

Background

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Discussion

Please log in to get access to this content

Other articles of this Issue 4/2014

A case of acute traumatic subdural hematoma in a child with previous bilateral encephaloduroarteriosynangiosis

Maternal flu or fever, medications use in the first trimester and the risk for neural tube defects: a hospital-based case–control study in China

A bony human tail causing tethered cord syndrome: case report

Mechanisms of postoperative progression of steno-occlusive lesions in the posterior cerebral artery in moyamoya disease

Reply to “Mechanisms of postoperative progression of steno-occlusive lesions in the posterior cerebral artery in moyamoya disease”

Duplicated filum terminale in the absence of split cord malformation: a potential cause of failed detethering procedures